Send us Fan Mail

Summary:  Journavx was born of the search for an option to opioids for moderate to severe pain relief.  The early results are mixed, some claiming it to be a miracle drug, others dismayed with its lack of effectiveness and its side effects.  Since Journavx utilizes a novel (non-opioid) approach to severe pain relief, the drug was fast-tracked by the FDA, which is a process used to facilitate the development and expedite the review of drugs which provide unmet medical needs, and thereby provide faster access for patients.  Post marketing review is essential to fully defining this drug’s benefits and risks.  

Topics: 

·       Opioid Crisis  01:00

·       JOURNAVX – Moderate to Severe Acute Pain 01:30

·        Mechanism of Action – New!  02:00

·       FDA Fast Track – Novel Approach 03:30

·       Acute Pain = 14 Dayn Approval 05:00

·       Side Effects:  Nausea, Constipation, Headache

        Dizziness, Itching, Muscle Spasm. 05:30

·       Further Studies Needed…07:00

·       Precautions:  Liver Function and Drug Interactions 08:00

·       Dosing. 09:00

·       New Approach  Post Marketing Monitoring 11:00

·       Shared Anecdotal Reports 11:30

·       MedWatch – FDA 12:15

·       Journaling 14:00

·       Cause & Effect 14:30

·       Follow-Up! 15:00

Questions and comments to  [email protected]